PAREXEL To Continue To Provide Research, Development Services To Pfizer

(RTTNews) - PAREXEL International Corp. (PRXL), a leading global biopharmaceutical services provider, announced it has signed a services agreement with Pfizer Inc. PAREXEL will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio.

PAREXEL provides expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. It has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement.